Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer

Table 1 General information on 45 patients with advanced non-small cell lung cancer

Features	Basic information
Age	65 yr (35-83 yr)
Gender
Male	27
Female	18
Pathological type
Squamous cell carcinoma	10
Adenocarcinoma	35
Chemotherapy regimen
AP	13
GP	5
Pemetrexed monotherapy	16
Docetaxel monotherapy	11

AP: Pemetrexed + carboplatin; GP: Gemcitabine + cisplatin.

Table 2 Relationships between clinicopathological features and short-term efficacy

Clinicopathological features	Case	CR	PR	SD	PD	ORR	CBR	P value
Pathological type								0.848
Squamous cell carcinoma	10	0	2	6	2	20.0%	80.0%
Adenocarcinoma	35	0	8	22	5	22.9%	85.7%
Chemotherapy regimen								0.411
Dual-drug chemotherapy + Rh-endostain	18	0	5	11	2	27.8%	88.9%
Single-drug chemotherapy + Rh-endostain	27	0	5	17	5	18.5%	81.5%

ORR: Objective response rate; CBR: Clinical benefit rate; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressed disease.

Table 3 Incidences of adverse events, n (%)

AEs	Any grade	Grade III and above
Decreased hemoglobin	34 (75.6)	5 (11.1)
Leukopenia	16 (35.6)	0 (0)
Thrombocytopenia	14 (31.1)	1 (2.2)
Elevated transaminase	24 (53.3)	7 (15.6)
Nausea/vomiting	32 (71.1)	0 (0)
Constipation	1 (3.4)	0

AEs: Adverse events.